1. Patients launch $1.27 million crowdfunding campaign for ME/CFS gut microbiome study.
    Check out the website, Facebook and Twitter. Join in donate and spread the word!
The ePatient Revolution
Ryan Prior shares his experience and his thoughts from attending the Stanford Medicine X Conference as he contemplates the rising of the ePatient Revolution ...
Discuss the article on the Forums.

Kerr: Parvovirus B19 research

Discussion in 'Latest ME/CFS Research' started by Orla, Mar 31, 2010.

  1. Orla

    Orla Senior Member

    Messages:
    446
    Likes:
    38
    Gen Virol. 2010 Apr;91(Pt 4):893-7. Epub 2009 Dec 9.

    Antibody to parvovirus B19 nonstructural protein is associated with chronic arthralgia in patients with chronic fatigue syndrome/myalgic encephalomyelitis.

    Kerr JR, Gough J, Richards SC, Main J, Enlander D, McCreary M, Komaroff AL, Chia JK.

    Department of Cellular & Molecular Medicine, St George's University of London, London, UK. jkerr@sgul.ac.uk

    Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a neuro-immune disease of uncertain pathogenesis. Human parvovirus B19 infection has been shown to occur just prior to development of the onset of CFS/ME in several cases, although B19 seroprevalence studies do not show any significant differences between CFS/ME and controls. In this study, we analysed parvovirus B19 markers in CFS/ME patients (n=200), diagnosed according to Fukuda CDC criteria, and normal blood donors (n=200). Serum from each subject was tested for anti-B19 VP2 IgM and IgG (by Biotrin ELISA), anti-B19 NS1 IgM and IgG (by immunofluorescence), and B19 DNA (by real-time PCR). CFS/ME patients and normal blood donors had a similar B19 seroprevalence (75 % versus 78 %, respectively). Eighty-three CFS patients (41.5 %) as compared with fourteen (7 %) normal blood donors tested positive for anti-B19 NS1 IgG (chi(2)=64.8; P<0.0001; odds ratio=9.42, CI 5.11-17.38). Of these 83 patients, 61 complained of chronic joint pain, while 22 did not. Parvovirus B19 DNA was detected in serum of 11 CFS patients and none of the controls by Taqman real-time PCR (chi(2)=9.35, P<0.002). Positivity for anti-B19 NS1 IgG was associated with higher expression levels of the human CFS-associated genes NHLH1 and GABPA. As NS1 antibodies are thought to indicate chronic or severe courses of B19 infection, these findings suggest that although the seroprevalence of B19 in CFS patients is similar to controls, the immune control of the virus in these patients may not be efficient.
     
  2. Kati

    Kati Patient in training

    Messages:
    2,120
    Likes:
    1,769
    This is excellent news!!! Parvo, you reading??? :hug::tear::victory:

    ETA : Thanks Orla
     
  3. Navid

    Navid Senior Member

    Messages:
    411
    Likes:
    58
    i have sky hi parvo titres...

    what does this research mean...that parvo does play a role in cfids?

    thanks, lisa
     
  4. Dolphin

    Dolphin Senior Member

    Messages:
    6,870
    Likes:
    6,161
  5. _Kim_

    _Kim_ Guest

  6. Gemini

    Gemini Senior Member

    Messages:
    398
    Likes:
    301
    Thanks, Orla!

    Good cross-discipline work (infectious diseases & genetics)
    & rigorous testing.

    Gemini
     
  7. bananaman

    bananaman

    Messages:
    59
    Likes:
    1
    Bognor UK
    I saw this posted on The ME Association Facebook page.

    Note from Charles Shepherd:

    The disease modifying drugs I was referring to in the BBC radio interview yesterday included antivirals (eg valganciclovir), hormones (low dose cortisone), immunomodulators (eg TNF alpha inhibitors such as etanercept; B cell depletion using rituximab and inosine pranobex to stimulate NK cell activity) and the CNS stimulant modafinil

    Most of the current experimental therapies, and some others, were summarised in the feature in February ME Essential.

    The possibility of further clinical trials into the use of antiviral medication directed at specific sub-groups of ME/CFS patients (eg parvovirus induced ME/CFS), immunomodulation and melatonin (for more severe sleep disturbance) was discussed at the MRC Expert Group Workshop at Heythrop last November.

    And I have just received a preliminary proposal relating to the Ramsay Research Fund to look at another new and very experimental treatment that appears to have a role in reducing central (ie brain induced) fatigue.
     
  8. Cort

    Cort Phoenix Rising Founder

    Messages:
    7,025
    Likes:
    441
    Raleigh, NC
    How interesting; similar seroprevalence and controls in CFS patients - but signs again that that virus is active in CFS patients but not in the healthier controls. So similar to HHV6 and EBV findings....pathogen findings in CFS are continuing to build...When are the feds going to get serious about immune system in CFS?
     

See more popular forum discussions.

Share This Page